This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|December 14, 2022
Thermo Fisher Expands Biologics and Steriles Manufacturing Capabilities in China
Author(s)BioPharm International Editors
Thermo Fisher Scientific’s new facility in Hangzhou, China, is designed to boost biologics and sterile development and manufacturing capabilities in the Asia-Pacific region.
Advertisement
Thermo Fisher Scientific announced the opening of a new facility in Hangzhou, China, on Dec. 8, 2022. The 80,000 m² current good manufacturing practices (CGMP) facility is designed to boost biologics and sterile development and manufacturing capabilities in China and the greater Asia-Pacific region.
According to a company press release, the facility will offer integrated clinical and commercial drug substance and drug product capabilities. This includes process development, cell line development, biologics drug substance manufacturing, and sterile fill-finish. The company also plans to feature commercial packaging and labeling capabilities in the future as well as expand its on-site bioreactors capacity from 2000 L to 5000 L.
"Hangzhou is a strategic addition to our global pharma services network and the latest example of our commitment to meeting customer demands globally,” said Mike Shafer, senior vice-president and president, Pharma Services, Thermo Fisher Scientific, in the release. “We continue to invest in capabilities to support the manufacturing needs of our customers, enabling them to serve more patients throughout the world.”
“Thermo Fisher has been in China for 40 years, serving this market through its bioproduction, clinical research, and pharma services businesses,” said Hann Pang, president, Thermo Fisher China, in the release. “Committed to our ‘in China, for China’ localization strategy, we are enhancing our workflow capabilities to fully support pharmaceutical and biotechnology companies in China and worldwide in helping more local innovations go global.”
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5